GlobalData on MSN6d
Stealth faces another hurdle as FDA delays decision on Barth syndrome drugThe FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
US clinical-stage drug developer Stealth BioTherapeutics announced that the US Food and Drug Administration (FDA) has ...
Phys.org on MSN5d
Scientists Solve Long-Standing DNA Machinery MysterySMC proteins can reverse direction, reshaping DNA and solving key scientific debates. This discovery could impact research on ...
Nuclear magnetic resonance (NMR) spectroscopy is a technique that detects the chemical environment of atomic nuclei by the absorption of radio-frequency electromagnetic radiation when in the ...
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
Read more about F. Diane Barth L.C.S.W. Books by F. Diane Barth L.C.S.W.
What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...
News on rare diseases, including the development of new treatments, the challenges of diagnosis and treatment and the stories of patients and their families. The page features in-depth reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback